- Leading South Korean and U.S. medical experts to share clinical insights into regenerative medicine
- Austrian clinical study on 47 ACL rupture patients treated with SMART M-CELL published in peer-reviewed journal
LOS ANGELES, Oct. 14, 2026 /PRNewswire/ -- Miracell U.S. Inc., the U.S. subsidiary of South Korean stem cell technology pioneer Miracell, will host "Stem Cell Science Day 2026," a specialized seminar on regenerative medicine, in Los Angeles, California, on Sunday, Nov. 1.

The seminar will bring together medical professionals from South Korea and the United States to present the latest research developments and clinical findings in stem cell-based therapies. Participants will explore real-world clinical applications and potential healthcare integration of Miracell's proprietary SMART M-CELL system in the U.S.
The event will take place from 1:00 p.m. to 7:00 p.m. at The Equitable Building (14th Floor) on Wilshire Boulevard in Los Angeles. It is open to healthcare professionals—including physicians (MD/DO), nurse practitioners (NP), physician assistants (PA), and registered nurses (RN)—free of charge.
Leading Medical Experts to Present Advances in Regenerative Medicine
The seminar features three prominent practitioners from South Korea and the U.S. who will present emerging research and clinical outcomes across women's health, orthopedics, and anti-aging medicine:
International Study Highlights Clinical Outcomes of SMART M-CELL for ACL Injuries
Miracell's SMART M-CELL system continues to gain global academic traction. A research team led by Patrick Weninger, M.D., an orthopedic specialist in Vienna, Austria, recently published findings from a clinical study involving 47 patients with anterior cruciate ligament (ACL) ruptures (mean age: 28.1 years) in the SCIE-indexed Indian Journal of Orthopaedics (July 2026).
The study—titled "Autologous Peripheral Blood-Derived Stem Cells Combined with Platelet-Rich Plasma is Associated With Clinical and Radiological Improvement in Anterior Cruciate Ligament Ruptures—Preliminary Clinical and MRI Findings in 47 Consecutive Patients"—evaluated a non-surgical treatment combining autologous blood-derived cells and platelet-rich plasma (PRP).
Using the SMART M-CELL system, researchers isolated and concentrated CD34+-containing blood-derived stem cells (BSCs) from each patient. Combined with PRP, the preparation was administered to the injured ligament in a single non-surgical session. Over a 12-month follow-up period:
These findings highlight the potential of a tissue-preserving, biological approach to ACL management—offering an effective non-surgical alternative for selected patients.
U.S. Expansion and Global Collaboration
SMART M-CELL is an advanced cell separation system engineered to process autologous blood and bone marrow. In April 2026, Miracell received 510(k) clearance from the U.S. FDA for its SMART M-CELL blood-derived stem cell (BSC) and bone marrow-derived stem cell (BmSC) concentration systems and dedicated kits, establishing a solid foundation for its entry into the U.S. market.
Beyond clinical presentations, Stem Cell Science Day 2026 will feature panel discussions, interactive Q&A sessions, one-on-one consultations, and networking opportunities designed to foster long-term international collaboration in regenerative medicine.
Event Details
View original content to download multimedia:https://www.prnewswire.com/news-releases/miracell-to-host-stem-cell-science-day-2026-in-los-angeles-featuring-international-clinical-insights-in-regenerative-medicine-302908377.html
SOURCE Miracell